Ready for Transfer

Use of Sterculic Acid to Treat Choroidal Neovascularization

Dept. of Health and Human Services

Sterculic acid is a naturally occurring fatty acid found in the seeds of several plants. NEI investigators have recently discovered that sterculic acid is a potent inhibitor of oxidized lipid-mediated inflammation both in vitro and in vivo. Sterculic acid has potent anti-angiogenic activity and daily drops can inhibit choroidal neovascularization in the retina of laser treated rats.

The present invention is directed to methods of using sterculic acid for the treatment of inflammation; in particular, 7-ketocholesterol (7KCh) mediated inflammation, neural cytotoxicity and angiogenesis. 7KCh is a potent VEGF inducer and sterculic acid can completely ablate this induction. Diseases suspected of being mediated by 7KCh-induced inflammation/cytotoxicity include atherosclerosis, age-related macular degeneration, and Alzheimer’s disease. Diseases mediated by unregulated angiogenesis include certain cancers and age-related macular degeneration. Also disclosed are methods of treating atherosclerosis or Alzheimer’s disease using sterculic acid.

Ignacio R. Rodriguez, Ph.D., National Eye Institute
William Samuel, Ph.D., National Eye Institute

Development Status
In vitro and animal model data have been collected, a patent application has been filed. This technology is appropriate for further development through a CRADA or license.

DHHS Reference No. E-092-2010

Licensing Contact
Sury Vepa, Ph.D., J.D.
Office of Technology Transfer
National Institutes of Health